Potential use of pharmacological markers to quantitatively assess liver function during liver transplantation surgery

Anaesthesia and Intensive Care

Volumn 28, Issue 4, 2000, Pages 375-385

  Gao, L ^a   Ramzan, I ^a   Baker, A B ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Measurement techniques: Pharmacological probes, graft liver function, liver transplantation

Indexed keywords

4 ACETANISIDINE; ALLOPURINOL; AMINOPHENAZONE; CAFFEINE; DEETHYLLIDOCAINE; DRUG METABOLIZING ENZYME; ERYTHROMYCIN; GALACTOSE; INDOCYANINE GREEN; LIDOCAINE; LIVER ENZYME; NEUROMUSCULAR BLOCKING AGENT; PHENAZONE; ROCURONIUM; TRIMETHADIONE; VECURONIUM;

BREATH ANALYSIS; DRUG BLOOD LEVEL; DRUG METABOLISM; HUMAN; LIVER CLEARANCE; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; REVIEW;

EID: 0033859878     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x0002800404     Document Type: Review

References (76)

1. Sheil AG. The new age of liver transplantation. Aust NZJ Surg 1996; 66:698-706.
2. Greig PD, Woolf GM, Abecassis M, et al. Treatment of primary liver graft non-function with prostaglandin E1 results in increased graft and patient survival. Transplant Proc 1989; 21: 2385-2388.
3. Remmer H. The role of the liver in drug metabolism. Am J Med 1970; 49:617-629.
4. Oellerich M, Burdelski M, Lautz HU. Lidocaine metabolite formation as a measure of liver function in patients with cirrhosis. Ther Drug Monit 1990; 12:219-226.
5. Schroeder TJ, Gremse DA, Mansour ME. Lidocaine metabolism as an index of liver function in hepatic transplantation donors and recipients. Transplant Proc 1989; 21:2299-2301.
6. Huang YS, Lee SD, Deng JF, et al. Measuring Iidocaine-monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis. J Hepatol 1993; 19:140-147.
7. Schroter J, Wandel C, Bohrer H, Schmidt H, Bottiger BW, Martin E. Lignocaine metabolite formation: an indicator for liver dysfunction and predictor of survival in surgical intensive care patients. Anaesthesia 1995; 50:850-854.
8. Meyer-Wyss B, Renner E, Luo H, Scholer A. Assessment of lidocaine metabolite formation in comparision with other quantitative liver function tests. J Hepatol 1993; 19:133-139.
9. Olinga P, Maring JK, Groothuis GMM, et al. Value of the in vitro or in vivo mono-ethylglycinexylidide test for predicting liver graft function. Transplantation 1997; 64:60-65.
10. Dette K, Knoop M, Langrehr JM. Donor MEGX test fails to predict graft liver function after orthotopic liver transplant. Transplant Proc 1997; 29:376-377.
11. Freys G, Pottecher T, Calon B, et al. Early assessment of transplanted liver function: Lignocaine clearance test (MEGX). Eur J Anaesthesiol 1997; 14:397-405.
12. Fox IJ, Brooker LGS, Heseltine DW, et al. Tricarbocyanine dye for continuous recording of dilution curves in whole blood independent of variations in blood oxygen saturation. Fed Proc 1957; 16:39.
13. Pollack DS, Sufian S, Matsumoto T. Indocyanine green clearance in critically ill patients. Surg Gynecol Obstet 1979; 149:852-854.
14. Caesar J, Shaldon S, Chiandussi L. The use of ICG in the measurement of hepatic blood flow and as a test of hepatic function. Clin Sci 1961; 21:43-57.
15. Jalan R, Plevris JN, Jalan AR, Finlayson NDC, Hayes PC. A pilot study of ICG clearance as an early predictor of graft function. Transplantation 1994; 58:196-200.
16. Tsubono T, Todo S, Jabbour N, et al. Indocyanine green elimination test in orthotopic liver recipients. Hepatology 1996; 24: 1165-1171.
17. Gilmore IT, Marigold JH, Thompson RPH. Half life time or clearance of ICG in patients with liver disease. Hepatogastroenterology 1982; 29:55-57.
18. Rodopoulos N, Wisen O, Norman A. Caffeine metabolism in patients with chronic liver disease. Scand J Clin Lab Invest 1995; 55:229-242.
19. Desmond PV, Patwardham RV, Johnson RF, Schenker S. Impaired elimination of caffeine in cirrhosis. Dig Dis Sci 1980; 25:193-197.
20. Calatayud O, Rodriguez M, Sanchez AA. Caffeine test assessment for measuring liver function in critically ill patients. J Clin Pharm Ther 1995; 20:23-29.
21. 14C-caffeine breath test. Pharmacol Toxicol 1995; 77:247-249.
22. Jover R, Carnicer F, Sanchez PJ, Climent E, Sirvent M, Marco JL. Salivary caffeine clearance predicts survival in patients with liver cirrhosis. Am J Gastroenterol 1997; 92:1905-1908.
23. Joeres R, Klinker H, Heusler H. Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver disease. Hepatology 1989; 8:575-579.
24. Grant DM, Tang BK, Campbell ME. Effects of allopurinol on caffeine disposition in man. Br J Clin Pharmacol 1986; 21:454-458.
25. Nagel RA, Dirix LY, Hayllar KM, Preisig R, Tredger JM, Williams R. Use of quantitative liver function test - caffeine clearance and galactose elimination capacity - after orthotopic liver transplantation. J Hepatol 1990; 10:149-157.
26. Keiding S, Johansen S, Winkler K. Michaelis-Menten kinetics of galactose elimination by the isolated perfused pig liver. Am J Physiol 1976; 230:1302-1313.
27. Keiding S, Johansen S, Tonnesen K. Kinetics of ethanol inhibition of galactose elimination in perfused pig liver. Scand J Clin Lab Invest 1977; 37:487-494.
28. Tygstrup N, Winkler K. Kinetics of galactose elimination. Acta Physiol Scand 1954; 32:354.
29. Ranek L, Andreasen PB, Tygstrup N. Galactose elimination capacity as a prognostic index in patients with fulminant liver failure. Gut 1976; 17:959-964.
30. Tygstrup N. Determination of the hepatic elimination capacity (Lm) of galactose by single injection. Scand J Clin Lab Invest(suppl) 1966; 92:118-125.
31. Merkel C, Gatta A, Zoli M, et al. Prognostic value of galactose elimination capacity, aminopyrine breath test, and ICG clearance in patients with cirrhosis. Dig Dis Sci 1991; 36:1197-1203.
32. Lindskov J. The quantitative liver function as measured by the galactose elimination capacity. Acta Med Scand 1982; 212:295-302.
33. Lamesch P, Ringe R, Oellerich M, et al. Assessment of liver function in the early postoperative period after liver transplantation with ICG, MEGX and GAL tests. Transplant Proc 1990; 22:1539-1541.
34. Tang HS, Hu OPY. Assessment of liver function using a novel galactose single point method. Digestion 1992; 52:222-231.
35. Hu OYP, Tang HS, Chang CL. Novel galactose single point method as a measure of residual liver function; example of cefoperazone kinetics in patients with liver cirrhosis. J Clin Pharmacol 1995; 35:250-258.
36. Fabrri A, Bianchi G, Brizi M. Uncertainty in liver function assessment on the basis of single-point galactose concentration. Digestion 1997; 58:379-383.
37. Vesell ES, Page JG. Genetic control of drug level in man: Antipyrine. Science 1968; 161:72-73.
38. Vesell ES. The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clin Pharmacol Ther 1979; 26:275-286.
39. Brodie BB, Axclrod J. The fate of antipyrine in man. J Pharmacol Exp Ther 1950; 98:97-104.
40. Vesell ES, Page JG. Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-life in man. J Clin Invest 1969; 48:2202-2209.
41. Teunissen MWE, Spoelstra P, Koch CW. Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis. Br J Clin Pharmacol 1984; 18:707-715.
42. Narange APS, Datta DV, Nath N. Impairment of hepatic drug metabolism in patients with acute viral hepatitis. Eur J Drug Metab Pharmacokinet 1982; 7:255-258.
43. St Peter JV, Awni WM. Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites. Clin Pharmacokinet 1991; 20:50-65.
44. Burnett DA, Barak AJ, Tuma DJ, Sorrell MF. Altered elimination of antipyrine in patients with acute viral hepatitis. Gut 1976; 17:341-344.
45. McPherson GAD, Benjamin IS, Boobis AR, Blumgart LH. Antipyrine elimination in patients with obstructive jaundice: A predictor of outcome. Am J Surg 1985; 149:140-143.
46. Luoma PV, Sotaniemi EA. Saliva and plasma clearance of antipyrine as reflectors of liver function. Eur J Drug Metab Pharmacokinet 1981; 6:261-264.
47. Mehta MU, Venkataramanan R, Burckart GJ, et al. Antipyrine kinetics in liver disease and liver transplantation. Clin Pharmacol Ther 1986; 39:372-377.
48. 14C-aminopyrine. Ann Intern Med 1975; 83:632-638.
49. Brodie BB, Axelrod J. The fate of aminopyrine in man and methods for estimation of aminopyrine and it's metabolites in biological materials. J Pharmacol Exp Ther 1950; 49:171-184.
50. 14C-aminopyrine. Effects of phenobarbital, disulfiram and portal cirrhosis. N Engl J Med 1974; 291:1384-1388.
51. 14C-aminopyrine breath test. Transplant Proc 1993; 25:2640-2641.
52. 14C-aminopyrine in liver diseases. Dig Dis Sci 1982; 27:49-56.
53. Morelli A, Narducci F, Pelli MA, Farroni F, Vedovelli A. The relationship between aminopyrine breath test and severity of liver disease in cirrhosis. Am J Gastroenterol 1981; 76:110-113.
54. Baker AL, Krager PS, Kotake AN. The aminopyrine breath test does not eorrelate with histologic severity in patients with cholestasis. Hepatology 1987; 7:464-467.
55. Oakland CDH, Hickman R, Terhlanche J. The aminopyrine breath test predicts the outcome of hepatic transplantation in pigs. Hepatology 1989; 9:602-605.
56. Tanaka E, Breimer DD. In vivo function tests of hepatic drug-oxidizing capacity in patients with liver disease. J Clin Pharm Ther 1997; 22:237-249.
57. 14C N-methyl erythromycin breath test in healthy male volunteers. J Clin Pharmacol 1998; 38:492-495.
58. Turgcon DK, Normolle DP, Leichtman AB, Annesley TM, Smith DE, Watkins PB. Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients. Clin Pharmacol Ther 1992; 52:471-478.
59. Cakaloglu Y, Tredger JM, Devlin J, Williams R. Importance of cyclosporine P-450 3A activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients. Hepatology 1994; 20:309-316.
60. Watkins PB, Hamilton TA, Annesley TM, Ellis CN, Kolars JC, Voorhees JJ. The erythromycin breath test as a predictor of cyclosporine blood levels. Pharmacokinet Drug Dispos 1990; 48:120-129.
61. Watkins PB, Turgeon DK, Saenger P, et al. Comparison of urinary 6-β-cortisol and the erythromycin breath test as measures of hepatic P 450 3A (CYP 3A) activity. Clin Pharmacol Ther 1992; 52:265-273.
62. Stein CM, Kinirons MT, Pincus T, Wilkinson GR, Wood AJJ. Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probe of CYP 3A activity in patients with rheumatoid arthritis receiving cyclosporine. Clin Pharmacol Ther 1996; 59:47-51.
63. Lukin CL, Hein HAT, Swygert TH, et al. Duration of vecuronium-induced neuromuscular block as a predictor of liver allograft dysfunction. Anesth Analg 1995; 80:526-533.
64. Marcel RJ, Ramsay MAE, Hein HAT, et al. Duration of rocuronium-induced neuromuscular block during liver transplantation: a predictor of primary allograft function. Anesth Analg 1997; 84:870-874.
65. Bencini AF, Scaf AH, Sohn YJ, Kersten-Kleef UW, Agoston S. Hepatobiliary disposition of vecuronium bromide in man. Br J Anaesth 1986; 58:988-995.
66. Bencini AF, Mol WEM, Scaf AHJ, et al. Uptake and excretion of vecuronium bromide and pancuronium bromide in the isolated perfused rat liver. Anesthesiology 1988; 69:487-492.
67. Magorian T, Wood P, Caldwell J, et al. The pharmacokinetics and neuromuscular effects of rocuronium bromide in patients with liver disease. Anesth Analg 1995; 80:754-759.
68. Ishikawa A, Fukao K, Tsuji K, et al. Trimethadione tolerance tests for the assessment of feasible size of hepatic resection in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 1993; 8:426-432.
69. Barstow L, Small RE. Liver function assessment by drug metabolism. Pharmacotherapy 1990; 10:280-288.
70. Ishikawa A, Fukao K, Tanaka E, et al. Trimethadione tolerance test for the quantitative assessment of liver function in rats. J Gastroenterol Hepatol 1991; 6:363-367.
71. Tanaka E, Kinoshita H, Yoshida T, Kuroiwa Y. Trimethadione as a model drug for the evaluation of hepatic drug-metabolizing capacity in normal and a-naphthylisothiocyanate intoxicated rats. Pharmacology 1982; 25:202-209.
72. Tanaka E, Ishikawa A, Fukao K, et al. Trimethadione tolerance test for one-point estimation of the severity of liver damage in cirrhotic patients. Int J Clin Pharmaeol Ther Toxicol 1991; 29:333-336.
73. 13C-methacelin breath test for quantitative liver function testing. Z Gastroenterol 1997; 35:609-614.
74. Krumbiegel P, Teichmann B, Faust H, Braun W. [15N] methacetin urine test to measure liver function: methodology for application in pediatrics. J Pediatr Gastroenterol Nutr 1988; 7:333-340.
75. Krumbiegel P, Teichmann B, Boehm G. [15N] methacetin urine test: a method to study the development of hepatic detoxification capacity. Scand J Clin Lab Invest 1988; 48:45-57.
76. Swank LA, Chejfec G, Nemchausky BA. Allopurinol-induced granulomatous hepatitis with cholangitis and a sarcoid-like reaction. Arch Intern Med 1978; 138:997-998.